title: How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
abstract: In past years, a diagnosis of bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplant (HCT) conferred nearly universal mortality secondary to lack of consensus for diagnostic criteria, poorly understood disease pathogenesis, and very few studies of therapeutic or supportive care interventions. Recently, however, progress has been made in these areas: revised consensus diagnostic guidelines are now available, supportive care has improved, there is greater understanding of potential mechanisms of disease, and prospective trials are being conducted. This article describes these advances and provides suggestions to optimize therapy for patients with BOS after HCT.
authors.affiliation: Center for Cancer and Blood Disorders, Children's National Health System, Washington, DC; and Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
authors.forename: Kirsten M
authors.identifier: 0000-0001-9372-5286
authors.initials: KM
authors.lastname: Williams
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001989:Bronchiolitis Obliterans / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D002675:Child, Preschool; D016903:Drug Monitoring; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007938:Leukemia / Q000276:immunology / Q000473:pathology / Q000628:therapy; D008297:Male; D017410:Practice Guidelines as Topic; D012129:Respiratory Function Tests; D012307:Risk Factors; D013577:Syndrome; D014184:Transplantation, Homologous
chemical_list: D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents